Healthcare interview preparation

Choose a healthcare subsector before building a financial forecast. Explain who pays, which evidence permits revenue, and what cash must be committed before the next decision.

Reviewed 21 October 2026.

Choose the business and the payer

A hospital delivers care and collects from several payer categories. Device companies sell equipment, implants, supplies or services. Pharmaceutical companies sell approved products, license rights, or fund an unapproved pipeline. Their revenue drivers and capital needs differ even when serving the same patient population.

Identify the customer, decision-maker and payer. Permission to market a product does not establish coverage, net reimbursement or adoption. A clinical idea needs a commercial and financing explanation. A valuation model cannot establish efficacy.

A forecast should follow the subsector
Business	Operating evidence to examine	Investment needed
Care provider	Patient volumes, service mix, payer mix and collections	Clinical labor, facilities, equipment and receivables
Medical devices	Procedure demand, installed base, product mix and recurring supplies	Development, production capacity, inventory and service support
Marketed pharmaceuticals	Patients treated, net price, product life and competition	Manufacturing, inventory and continuing development
Pre-revenue drug developer	Trial stage, endpoints, milestones and remaining cash	Research spending before a marketable product exists

Bridge activity to revenue and cash

Separate patient activity from revenue per unit. Same-facility growth helps distinguish operating changes from acquisitions. Check whether admissions include outpatient activity through an equivalent-admission adjustment. Occupancy needs context on staffing capacity and service mix.

HCA's 2025 report identifies payer mix, claim processing and revenue-cycle operations as factors affecting collections. It also discusses clinical labor costs and capital spending. Use those disclosures to prepare a bridge from activity and reimbursement through labor, supplies, receivables and capex.

CMS describes Medicare acute inpatient payment through prospectively set rates and diagnosis-related groups. List charges therefore differ from collections and net revenue. Identify payer and reimbursement assumptions, including contractual adjustments, before projecting revenue.

Keep receivable days consistent with the revenue definition and period. Growth can require cash before claims settle. Combine slower collections with wage pressure in a downside, and identify facility projects that can be delayed while preserving maintenance.

Sources: HCA Healthcare 2025 Annual Report to Shareholders; Acute Inpatient PPS.

Build product economics and a finite life

For devices, separate equipment placements from recurring procedures or consumables. Installed units need utilization and associated purchases to produce revenue. Examine pricing, replacement cycles and warranty obligations. Distinguish product launches from acquired sales.

For an approved pharmaceutical product, build treated patients and net realized price after the deductions relevant to that market. Consider indication, patient access, competing therapies and the remaining period of exclusivity. A perpetual terminal growth assumption can obscure a finite commercial life. Manufacturing capacity, quality requirements and inventory are cash commitments even when product margins appear attractive.

Separate R&D, capex and acquired intangibles. Mature-company EBITDA can aid comparison after consistent adjustments, but omits capex and working capital. Adding back recurring development spending without funding future products overstates sustainable economics.

Model development risk by stage

The FDA describes discovery, preclinical work, clinical research, review and post-market monitoring as distinct steps. Clinical phases investigate different questions. Progression through one phase does not establish eventual approval, and the timing and requirements depend on the program. Read what a trial's endpoints and remaining work mean before choosing a financial scenario.

EV/EBITDA is unsuitable when a pre-revenue developer has no meaningful recurring earnings. A generic industrial DCF also misses the conditional spending and possible failure of individual programs. A risk-adjusted project valuation should specify which costs occur regardless of outcome and which arise only if an earlier gate is passed. Discount the dated expected cash flows consistently; avoid adding an unexplained second failure haircut through the discount rate.

Use program-specific evidence when constructing real probabilities. Published phase averages are not a forecast for a named drug. The exercise below deliberately supplies fictional probabilities so the arithmetic can be checked without making a clinical claim.

A staged research program can stop spending after failure

Calculate the project's expected net present value and explain how the spending gates change the answer.

Every input is fictional. At time 0, pay $12 million for the first stage. At the end of year 1, the first gate has a 40% chance of success.
If that gate succeeds, immediately pay $20 million at the end of year 1. Conditional on passing the first gate, a final outcome at the end of year 3 has a 50% chance of success.
Final success produces $150 million of net sale proceeds at the end of year 3. Either failure produces zero proceeds and stops all further spending. There are no other cash flows, taxes, debt, fees or residual value.
Use a 10% annual discount rate solely as an illustrative time-value assumption. Probabilities already capture the specified binary outcome risks.

Show the worked reasoning

Joint success probability = 40% × 50% = 20%. Expected year-3 proceeds = 20% × $150m = $30m.
The year-1 payment depends only on passing the first gate. Expected payment = 40% × $20m = $8m.
Present value of proceeds = $30m / 1.10^3 = $22.539m. Present value of later spending = $8m / 1.10 = $7.273m.
Expected NPV = -$12m - $7.273m + $22.539m = $3.267m, or about $3.27m.

The simplified project has positive expected NPV of $3.27 million under these assumptions. That is a scenario calculation; the real decision would need defensible probabilities, costs, rights, timing and financing.

Check your reasoning: Weighting the year-1 cost by the 20% final success probability understates spending. Programs that pass the first gate but fail later still incur that $20 million.

Sources: The Drug Development Process; Step 3: Clinical Research.

Read the rights and funding in a healthcare transaction

A full-company acquisition transfers a different package from a product license or asset acquisition. For a license, identify territory, indications, exclusivity, upfront consideration, development responsibilities, milestones and royalties. Contingent consideration allocates some risk; a headline maximum milestone total is not cash paid at signing or a probability-weighted price.

For provider deals, investigate payer contracts, physician relationships, facility investment and liabilities. For devices, include quality, service obligations and intellectual property. These are diligence questions; evidence must establish whether a named company has a problem.

A financing plan should reach a defined evidence event with enough cash for a delay. A positive expected project NPV does not ensure the company survives until the next readout. New equity, preferred terms and possible later dilution belong beside the operating scenario.

Prepare one subsector explanation in depth

Choose a provider, device manufacturer or developer. Explain its revenue driver and largest cash uncertainty in two minutes. Defend one valuation method and reject one unsuitable denominator.

Use FinTwin's accounting, DCF and contingent-consideration foundations for the relevant mechanics. SignalDock can sharpen financing and runway reasoning, but its subscription business is not a biotechnology model. The catalogue has no specialized clinical pipeline or healthcare reimbursement model; completing a general case does not fill that sector gap.

Your next actions

Identify the customer, payer and reimbursement or commercial-access assumptions.
Choose operating units that match the subsector and keep same-facility comparisons consistent.
Separate mandatory cash spending from costs conditional on a milestone.
Show a delay or failure scenario and cash needed to reach the next evidence event.
Explain the rights and contingent payments included in a transaction.

Put it into practice

Choose the first task that matches your preparation. These links open the FinTwin study workspace under its normal account and saved-work rules.

Separate profit from cash
Build the accounting foundation for explaining revenue recognized before collection.
Translate operating days into cash
Convert a collections delay into cash required by a provider or manufacturer.
Discount cash flows and terminal value
Practise dated cash values before building a separate conditional pipeline forecast.
Separate an earnout's expected cash and fair value
Challenge the difference between a headline contingent payment and its expected value.
SignalDock: finance a renewal cliff
Practise a dated cash shortage and financing choice, while keeping the software assumptions distinct from clinical development.

Try the task before revealing its worked answer. Compare the method, revise your reasoning and use the workspace’s save or review controls. Reading this guide does not record a completed lesson.

Sources and scope

FDA, CMS and HCA disclosures support the process and reporting distinctions. The preparation approach and research-project calculation are original educational material. Example probabilities and cash flows are fictional, not clinical success estimates or advice about a real treatment or security.

The linked company disclosures and regulatory pages support the definitions and factual examples above. Reporting periods and company-specific metrics matter. Numerical exercises and preparation advice are original FinTwin teaching.

HCA Healthcare 2025 Annual Report to Shareholders — HCA Healthcare. Checked 21 October 2026. Year ended December 31, 2025.
Acute Inpatient PPS — Centers for Medicare & Medicaid Services. Checked 21 October 2026.
The Drug Development Process — US Food and Drug Administration. Checked 21 October 2026.
Step 3: Clinical Research — US Food and Drug Administration. Checked 21 October 2026.